2m 2m 2m 2m 2m 2m 2m
Fate Therapeutic (FATE)
NASDAQ
$2.21-$0.009 (-0.41%)
Price as of Jun 03, 2026 7:56 PM EDT- $331.0MMarket Cap
- 56.34%1-Year Change
- BiotechnologyIndustry
Fate Therapeutic (FATE)
$2.21-$0.009 (-0.41%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 6.6M -51.24% | 13.6M -78.55% | 63.5M -34.03% | 96.3M +72.44% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 6.6M -51.24% | 13.6M -78.55% | 63.5M -34.03% | 96.3M +72.44% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -107.8M -20.13% | -135.0M -21.78% | -172.6M -46.14% | -320.5M +48.69% | |
Depreciation and Amortization Expense | 12.9M -31.96% | 19.0M +3.72% | 18.3M +32.88% | 13.8M +135.18% | |
Total Operating Expenses | 154.3M -31.07% | 223.9M -11.86% | 254.0M -37.22% | 404.7M +48.32% | |
Operating Profit | -147.7M -29.76% | -210.3M +10.37% | -190.5M -38.22% | -308.4M +42.12% | |
Interest Income | 11.1M -36.07% | 17.3M +0.59% | 17.2M +194.18% | 5.8M +346.29% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 11.1M -36.07% | 17.3M +0.59% | 17.2M +194.18% | 5.8M +346.29% | |
Total Nonoperating Income and Expense | 11.4M -52.57% | 24.0M -18.83% | 29.6M +10.94% | 26.7M +450.59% | |
Income before Taxes | -147.7M -29.76% | -210.3M +10.37% | -190.5M -38.22% | -308.4M +42.12% | |
Income Taxes | 2,000 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | 0 -100.00% | 13.4M N/A | N/A N/A | N/A N/A | |
Net Income | -136.3M -26.82% | -186.3M +15.74% | -160.9M -42.88% | -281.7M +32.79% | |
Net Income from Continuing Operations Applicable to Common | -136.3M -26.82% | -186.3M +15.74% | -160.9M -42.88% | -281.7M +32.79% | |
Basic EPS and Net Income | -1.15 -29.88% | -1.64 0.00% | -1.64 -43.64% | -2.91 +29.91% | |
Diluted EPS and Net Income | -1.15 -29.88% | -1.64 0.00% | -1.64 -43.64% | -2.91 +29.91% | |
Basic Weighted Average Shares | 118.8M +4.49% | 113.7M +15.52% | 98.4M +1.64% | 96.8M +2.19% | |
Diluted Weighted Average Shares | 118.8M +4.49% | 113.7M +15.52% | 98.4M +1.64% | 96.8M +2.19% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 46.6M +29.32% | 36.1M -13.89% | 41.9M -31.73% | 61.3M -54.09% | |
Short-Term Investments | 157.0M -35.38% | 243.0M -11.08% | 273.3M -27.10% | 374.9M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 203.7M -27.02% | 279.1M -11.46% | 315.2M -27.75% | 436.2M +226.56% | |
Total Current Assets | 208.7M -28.50% | 291.9M -11.95% | 331.5M -33.97% | 502.1M -20.74% | |
Accumulated Depreciation | 36.2M +3.09% | 35.1M -26.23% | 47.6M +56.75% | 30.4M +79.31% | |
Property and Plant and Equipment and Net | 56.9M -11.59% | 64.4M -33.51% | 96.8M -11.98% | 110.0M +20.20% | |
Total Long-Term Assets | 0 -100.00% | 9,000 0.00% | 9,000 -72.73% | 33,000 0.00% | |
Total Assets | 318.9M -27.63% | 440.7M -12.94% | 506.2M -28.25% | 705.6M -23.43% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 36.1M -6.36% | 38.5M -1.46% | 39.1M -65.72% | 114.1M +40.31% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 73.3M -5.86% | 77.8M -20.04% | 97.4M -6.12% | 103.7M -23.95% | |
Total Liabilities | 109.4M -6.03% | 116.4M -14.72% | 136.5M -37.34% | 217.8M +14.30% | |
Retained Earnings | -1.5B +9.75% | -1.4B +15.37% | -1.2B +15.31% | -1.1B +36.63% | |
Total Stockholders Equity | 207.2M -35.00% | 318.7M -13.49% | 368.4M -23.87% | 483.9M -28.71% | |
Total Shares Outstanding | 115.4M +1.26% | 113.9M +15.51% | 98.6M +1.37% | 97.3M +1.64% | |
Cash Flow | |||||
Cash from Operating Activities | -106.1M -13.66% | -122.9M -7.10% | -132.3M -46.71% | -248.2M +52.40% | |
Capital Expenditures | 6.0M +715.48% | 730,000 -88.14% | 6.2M -82.70% | 35.6M -29.86% | |
Cash from Investing Activities | 111.2M +809.85% | 12.2M -89.16% | 112.7M -32.44% | 166.8M +151.46% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 5.5M -94.50% | 99.9M +117,420.00% | 85,000 -99.08% | 9.2M -97.97% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -2,222.45% +44.07% | -1,542.63% +414.45% | -299.86% -6.36% | -320.23% -17.58% | |
Return on Assets | -35.89% -8.77% | -39.34% +48.12% | -26.56% -23.30% | -34.63% +26.01% | |
Return on Equity | -51.84% -4.38% | -54.21% +43.57% | -37.76% -22.07% | -48.46% +21.43% | |
Revenue Growth | -51.24% -34.76% | -78.54% +130.84% | -34.03% -146.97% | 72.44% -6.72% | |
Current Ratio | 5.79 -23.65% | 7.58 -10.65% | 8.48 +92.64% | 4.40 -43.51% | |
Cash Ratio | 1.29 +38.11% | 0.94 -12.61% | 1.07 +99.14% | 0.54 -67.28% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow